Prognostic impact of shift to low visceral fat mass after neoadjuvant chemotherapy in patients with esophageal cancer

Abstract Background Based on the JCOG1109 trial, it is suggested that the combination of docetaxel, cisplatin, and 5‐fluorouracil (DCF) could potentially become a standard neoadjuvant chemotherapy regimen, alongside the conventional 5‐fluorouracil and cisplatin (CF) therapy, for esophageal cancer. H...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Sachiyo Onishi, Masahiro Tajika, Tsutomu Tanaka, Keisaku Yamada, Yoshitaka Inaba, Tetsuya Abe, Kei Muro, Masahito Shimizu, Yasumasa Niwa
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Wiley 2024-08-01
Reeks:	Cancer Reports
Onderwerpen:	esophageal cancer neoadjuvant chemotherapy sarcopenia shift to low visceral fat mass
Online toegang:	https://doi.org/10.1002/cnr2.2084
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!